New lawsuits target Johnson & Johnson and Eli Lilly, alleging that antipsychotic medications Risperdal, Invega, and Zyprexa carry undisclosed breast cancer risks, potentially impacting long-term legal liabilities.
Johnson & Johnson faces mounting legal challenges as Wisner Baum lawsuits allege the company failed to adequately warn patients and medical professionals about breast cancer risks linked to its antipsychotic medications, Risperdal and Invega. These claims are supported by emerging research suggesting a correlation between prolactin-elevating drugs and an increased incidence of breast cancer, creating significant legal and reputational exposure for the firm.
The lawsuits allege that JNJ failed to warn patients and physicians about the breast cancer risks associated with Risperdal and Invega.
Eli Lilly is implicated in the same wave of litigation as Wisner Baum targets manufacturers of prolactin-elevating antipsychotics for failing to disclose breast cancer risks. The inclusion of Zyprexa in these lawsuits exposes Eli Lilly to potential liability similar to that faced by other pharmaceutical manufacturers, as plaintiffs argue that the drug's side effect profile was not sufficiently communicated.
Zyprexa is being targeted because it is a prolactin-elevating antipsychotic, which plaintiffs allege is linked to an increased risk of breast cancer.
Johnson & Johnson and Eli Lilly face mounting legal pressure as Wisner Baum files lawsuits alleging failure to warn patients of breast cancer risks linked to Risperdal, Invega, and Zyprexa. The litigation centers on the drugs' tendency to elevate prolactin levels, which emerging research suggests may increase cancer susceptibility.
The lawsuits allege that the companies failed to adequately warn about the increased risk of breast cancer associated with the use of their antipsychotic medications.